{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:31:05Z","timestamp":1790775065652,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021546","name":"Suez University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021546","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a growing public health challenge in Egypt, driven by westernized dietary patterns, urbanization, and physical inactivity. Despite lifestyle intervention being the first-line management, data on structured hypocaloric diets tailored to Egyptian patients remain limited, particularly regarding their effects on hepatic steatosis, inflammatory pathways, and oxidative stress biomarkers. This study aimed to evaluate the impact of a culturally adapted 6-month hypocaloric diet on hepatic fat reduction, metabolic parameters, inflammatory-oxidative biomarkers, and lifestyle factors in Egyptian MASLD patients, with additional exploration of weight-independent mechanisms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this single-center interventional trial, 30 newly diagnosed MASLD patients received a personalized hypocaloric diet (500\u20131000\u00a0kcal\/day deficit). Outcomes measured at baseline and post-intervention included anthropometrics, liver enzymes, metabolic profile, hepatic steatosis (CAP score), inflammatory markers (TNF-\u03b1, MDA), antioxidant enzymes (SOD, CAT), and lifestyle behaviors (physical activity, sleep). Advanced statistical analyses included effect size estimation, multivariate regression, mediation analysis, and subgroup comparisons (lean vs. obese MASLD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>After 6\u00a0months, patients achieved significant reductions in weight (\u2212\u200910.9\u00a0kg), BMI (\u2212\u20093.9\u00a0kg\/m<jats:sup>2<\/jats:sup>), and CAP score (\u2212\u200989.5\u00a0dB\/m) (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Liver enzymes improved significantly, with ALT decreasing by\u2009\u2212\u200922.2 U\/L and AST by\u2009\u2212\u200921.3 U\/L (both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). TNF-\u03b1 (\u2212\u200988.2\u00a0pg\/mL, baseline 166.1\u00a0pg\/mL) and MDA (\u2212\u20091.1\u00a0nmol\/mL, baseline 2.7\u00a0nmol\/mL) decreased markedly, with large effect sizes (CAP: <jats:italic>d<\/jats:italic>\u2009=\u20091.9; TNF-\u03b1: <jats:italic>d<\/jats:italic>\u2009=\u20092.1; MDA: <jats:italic>d<\/jats:italic>\u2009=\u20091.4). Antioxidant biomarkers improved significantly, with SOD increasing by 209% (<jats:italic>d<\/jats:italic>\u2009=\u20091.8) and CAT by 48.5% (<jats:italic>d<\/jats:italic>\u2009=\u20091.2) (both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Although BMI and weight loss were strongly associated with hepatic fat reduction, TNF-\u03b1 reduction remained an independent predictor of CAP improvement (\u03b2\u2009=\u20090.31, <jats:italic>P<\/jats:italic>\u2009=\u20090.02), mediating 32% of the diet\u2019s effect after adjusting for BMI. Patients achieving\u2009\u2265\u20095% weight loss were 4.2 times more likely to experience\u2009\u2265\u200910% CAP score reduction. Lean MASLD patients (n\u2009=\u20096) exhibited greater improvements in hepatic fat and inflammation despite less weight loss; however, these findings should be interpreted with caution due to the small subgroup size. Dietary adherence strongly correlated with CAP reduction (<jats:italic>r<\/jats:italic>\u2009= \u2212\u20090.71, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and antioxidant gains.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>A culturally tailored hypocaloric diet effectively improved hepatic steatosis, inflammatory status, and antioxidant capacity in Egyptian MASLD patients. These improvements were partially weight-independent and partially mediated by anti-inflammatory responses. These findings support hypocaloric dietary strategies as a potentially scalable therapeutic option for MASLD management in resource-limited settings, though the absence of a control group limits causal inference, and further evaluation of implementation feasibility and cost-effectiveness is warranted. Additional benefits were also observed in lifestyle behaviors such as physical activity and sleep.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12944-025-02710-7","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:35:28Z","timestamp":1758605728000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Culturally adapted hypocaloric diet improves hepatic steatosis, inflammatory and oxidative biomarkers in Egyptian MASLD patients: a single-arm interventional study"],"prefix":"10.1186","volume":"24","author":[{"given":"Mohamed Mahmoud","family":"Elhoseeny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Rageh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Bakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Elgamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar S.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar M.","family":"Rezk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira A. A.","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"issue":"7","key":"2710_CR1","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic-associated fatty liver disease. Gastroenterology. 2020;158(7):1999\u20132014.","journal-title":"Gastroenterology"},{"issue":"1","key":"2710_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"issue":"1","key":"2710_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-024-03310-y","volume":"24","author":"MM Elhoseeny","year":"2024","unstructured":"Elhoseeny MM, Abdulaziz BA, Mohamed MA, Elsharaby RM, Rashad GM, Othman AA. Fetuin-A: a relevant novel serum biomarker for non-invasive diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD): a retrospective case-control study. BMC Gastroenterol. 2024;24(1):226.","journal-title":"BMC Gastroenterol"},{"issue":"Suppl 2","key":"2710_CR4","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1007\/s12072-024-10662-w","volume":"18","author":"N M\u00e9ndez-S\u00e1nchez","year":"2024","unstructured":"M\u00e9ndez-S\u00e1nchez N, Brouwer WP, Lammert F, Yilmaz Y. Metabolic dysfunction associated with fatty liver disease in healthy weight individuals. Hep Intl. 2024;18(Suppl 2):884\u201396.","journal-title":"Hep Intl"},{"issue":"4","key":"2710_CR5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/liv.15852","volume":"44","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Paik J, Owrangi S, Yilmaz Y, El-Kassas M, et al. Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa. Liver Int. 2024;44(4):1061\u201370.","journal-title":"Liver Int"},{"issue":"4","key":"2710_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.jhep.2020.12.027","volume":"74","author":"M Eslam","year":"2021","unstructured":"Eslam M, George J. MAFLD: a holistic view to redefining fatty liver disease. J Hepatol. 2021;74(4):983\u20135.","journal-title":"J Hepatol"},{"issue":"4","key":"2710_CR7","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","volume":"17","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748\u201355.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"2710_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1290842","volume":"30","author":"MA Hegazy","year":"2024","unstructured":"Hegazy MA, Elshafei A, Salem MR, Ashoush O, Abdelghani A. Non-alcoholic fatty liver disease related knowledge among a sample of Egyptians: an exploratory cross-sectional study. Front Public Health. 2024;30(11):1290842.","journal-title":"Front Public Health"},{"issue":"3","key":"2710_CR9","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.21608\/ejhc.2022.342070","volume":"13","author":"Mustaf El Kotb W","year":"2022","unstructured":"El Kotb W Mustaf, Fawzy Hanafy N, El Waan W, Shokr E E. Diversified Program and Targeting Lifestyle Modification among Obese Patients with Non-Alcoholic Fatty Liver Disease. Egypt J Health Care. 2022;13(3):2217\u201333.","journal-title":"Egypt J Health Care."},{"issue":"1","key":"2710_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000780","volume":"8","author":"S Tomah","year":"2021","unstructured":"Tomah S, Hamdy O, Abuelmagd MM, Hassan AH, Alkhouri N, Al-Badri MR, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt. BMJ Open Gastroenterol. 2021;8(1):e000780.","journal-title":"BMJ Open Gastroenterol"},{"issue":"2","key":"2710_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ajg.2014.05.002","volume":"15","author":"YM Alkassabany","year":"2014","unstructured":"Alkassabany YM, Farghaly AG, El-Ghitany EM. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria. Egypt Arab J Gastroenterol. 2014;15(2):76\u201381.","journal-title":"Egypt Arab J Gastroenterol"},{"issue":"4","key":"2710_CR12","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/hep.20140","volume":"39","author":"LA Adams","year":"2004","unstructured":"Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology. 2004;39(4):909\u201314.","journal-title":"Hepatology"},{"issue":"3","key":"2710_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"A Berzigotti","year":"2021","unstructured":"Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, et al. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20132021 update. J Hepatol. 2021;75(3):659\u201389.","journal-title":"J Hepatol"},{"issue":"1","key":"2710_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.metabol.2016.12.006","volume":"68","author":"CN Katsagoni","year":"2017","unstructured":"Katsagoni CN, Georgoulis M, Papatheodoridis GV, Panagiotakos DB, Kontogianni MD. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: a meta-analysis. Metabolism. 2017;68(1):119\u201332.","journal-title":"Metabolism"},{"key":"2710_CR15","doi-asserted-by":"publisher","unstructured":"Bujang MA, Ab Ghani P, Soelar SA, Zulkifli NA. Sample size guideline for exploratory factor analysis when using small sample: Taking into consideration of different measurement scales. In: 2012 International Conference on Statistics in Science, Business and Engineering (ICSSBE); 2012; Langkawi, Malaysia. Piscataway, NJ: IEEE; 2012. p. 1\u20135. https:\/\/doi.org\/10.1109\/ICSSBE.2012.6396602.","DOI":"10.1109\/ICSSBE.2012.6396602"},{"issue":"6","key":"2710_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/MBP.0000000000000547","volume":"26","author":"P Zhang","year":"2021","unstructured":"Zhang P, Li X, Fang Z, Lu Y, Cui J, Du X, et al. Smartphone application-supported validation of three automatic devices for self-measurement of blood pressure according to the European Society of Hypertension International Protocol revision 2010: the Omron HEM-7120, Yuwell YE680A, and Cofoe KF-65 B. Blood Press Monit. 2021;26(6):435\u201340.","journal-title":"Blood Press Monit"},{"issue":"3","key":"2710_CR17","first-page":"1141","volume":"78","author":"P Liana","year":"2023","unstructured":"Liana P, Jenica A, Suciati T, Rahmawati E, Pariyana P, Umar TP. Comparison of liver function test results between Architect C8000 and COBAS C501 automatic chemistry analyzer. Arch Razi Inst. 2023;78(3):1141.","journal-title":"Arch Razi Inst"},{"issue":"3","key":"2710_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s13679-023-00519-y","volume":"12","author":"ID Vachliotis","year":"2023","unstructured":"Vachliotis ID, Polyzos SA. The role of tumor necrosis factor-alpha in the pathogenesis and treatment of nonalcoholic fatty liver disease. Curr Obes Rep. 2023;12(3):191\u2013206.","journal-title":"Curr Obes Rep"},{"issue":"7","key":"2710_CR19","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jand.2013.08.019","volume":"114","author":"RF Tayyem","year":"2014","unstructured":"Tayyem RF, Abu-Mweis SS, Bawadi HA, Agraib L, Bani-Hani K. Validation of a food frequency questionnaire to assess macronutrient and micronutrient intake among Jordanians. J Acad Nutr Diet. 2014;114(7):1046\u201352.","journal-title":"J Acad Nutr Diet"},{"issue":"5","key":"2710_CR20","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/hep.30076","volume":"68","author":"C Properzi","year":"2018","unstructured":"Properzi C, O\u2019Sullivan TA, Sherriff JL, Ching HL, Jeffrey GP, Buckley RF, et al. Ad libitum Mediterranean and low-fat diets both significantly reduce hepatic steatosis: a randomized controlled trial. Hepatology. 2018;68(5):1741\u201354.","journal-title":"Hepatology"},{"issue":"S2","key":"2710_CR21","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1017\/S0007114512002589","volume":"108","author":"MS Westerterp-Plantenga","year":"2012","unstructured":"Westerterp-Plantenga MS, Lemmens SG, Westerterp KR. Dietary protein\u2013its role in satiety, energetics, weight loss, and health. Br J Nutr. 2012;108(S2):S105-12.","journal-title":"Br J Nutr"},{"key":"2710_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/DMSO.S17322","volume":"8","author":"AO Musaiger","year":"2011","unstructured":"Musaiger AO, Al Hazzaa HM, Al-Qahtani A, Elati J, Ramadan J, AboulElla NA, et al. Strategy to combat obesity and to promote physical activity in Arab countries. Diabetes Metab Syndr Obesity. 2011;8:89\u201397.","journal-title":"Diabetes Metab Syndr Obesity"},{"issue":"9","key":"2710_CR23","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.3390\/ijerph8093810","volume":"8","author":"HM Al-Hazzaa","year":"2011","unstructured":"Al-Hazzaa HM, Al-Sobayel HI, Musaiger AO. Convergent validity of the Arab Teens Lifestyle Study (ATLS) physical activity questionnaire. Int J Environ Res Public Health. 2011;8(9):3810\u201320.","journal-title":"Int J Environ Res Public Health"},{"key":"2710_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s41105-018-0196-0","volume":"17","author":"S Hallit","year":"2019","unstructured":"Hallit S, Haddad C, Hallit R, Al Karaki G, Malaeb D, Sacre H, et al. Validation of selected sleeping disorders related scales in Arabic among the Lebanese population. Sleep Biol Rhythms. 2019;17:183\u20139 (Apr 15;).","journal-title":"Sleep Biol Rhythms"},{"issue":"5","key":"2710_CR25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0168-8278(03)00097-7","volume":"38","author":"SF Solga","year":"2003","unstructured":"Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen\u2013liver interactions and possible role for probiotics. J Hepatol. 2003;38(5):681\u20137.","journal-title":"J Hepatol"},{"issue":"6","key":"2710_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157358","volume":"11","author":"HW Lee","year":"2016","unstructured":"Lee HW, Park SY, Kim SU, Jang JY, Park H, Kim JK, et al. Discrimination of nonalcoholic steatohepatitis using transient elastography in patients with nonalcoholic fatty liver disease. PLoS ONE. 2016;11(6):e0157358.","journal-title":"PLoS ONE"},{"key":"2710_CR27","doi-asserted-by":"crossref","unstructured":"Elhoseeny MM, Rageh F, Rezk SM, Othman AA Amira. Frequency and risk factors of metabolic-associated fatty liver disease among medical students in Egypt. Scientific Reports. 2025; 15, 13470.","DOI":"10.1038\/s41598-025-95753-w"},{"issue":"1","key":"2710_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/sjg.sjg_357_21","volume":"28","author":"Y Fouad","year":"2022","unstructured":"Fouad Y, Esmat G, Elwakil R, Zakaria S, Yosry A, Waked I, et al. The Egyptian clinical practice guidelines for the diagnosis and management of metabolic-associated fatty liver disease. Saudi J Gastroenterol. 2022;28(1):3\u201320.","journal-title":"Saudi J Gastroenterol"},{"issue":"8","key":"2710_CR29","first-page":"572","volume":"41","author":"EM Said","year":"2024","unstructured":"Said EM, Fouad YM, Abo-Amer YE, Zidan MS, Kandil AE. Impact of metabolic associated fatty liver disease on health-related quality of life. Benha Med J. 2024;41(8):572\u201384.","journal-title":"Benha Med J"},{"issue":"2","key":"2710_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1017\/S000711451800137X","volume":"120","author":"CN Katsagoni","year":"2018","unstructured":"Katsagoni CN, Papatheodoridis GV, Ioannidou P, Deutsch M, Alexopoulou A, Papadopoulos N, et al. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. Br J Nutr. 2018;120(2):164\u201375.","journal-title":"Br J Nutr"},{"issue":"7","key":"2710_CR31","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.cgh.2013.11.017","volume":"12","author":"A Siddique","year":"2014","unstructured":"Siddique A, Nelson JE, Aouizerat B, Yeh MM, Kowdley KV. NASH Clinical Research Network. Iron deficiency in patients with nonalcoholic fatty liver disease is associated with obesity, female gender, and low serum hepcidin. Clin Gastroenterol Hepatol. 2014;12(7):1170\u20138.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"2710_CR32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11154-020-09621-1","volume":"22","author":"S Maier","year":"2021","unstructured":"Maier S, Wieland A, Cree-Green M, Nadeau K, Sullivan S, Lanaspa MA, et al. Lean NAFLD: an underrecognized and challenging disorder in medicine. Rev Endocr Metab Disord. 2021;22(2):351\u201366.","journal-title":"Rev Endocr Metab Disord"},{"issue":"1\/3","key":"2710_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000228996","volume":"55","author":"I Elmadfa","year":"2009","unstructured":"Elmadfa I, Kornsteiner M. Fats and fatty acid requirements for adults. Ann Nutr Metab. 2009;55(1\/3):56\u201375.","journal-title":"Ann Nutr Metab"},{"issue":"4","key":"2710_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jhepr.2019.08.002","volume":"1","author":"S Albhaisi","year":"2019","unstructured":"Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2019;1(4):329\u201341.","journal-title":"JHEP Rep"},{"key":"2710_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1217249","volume":"14","author":"M Chen","year":"2023","unstructured":"Chen M, Cao Y, Ji G, Zhang L. Lean nonalcoholic fatty liver disease and sarcopenia. Front Endocrinol. 2023;14:1217249.","journal-title":"Front Endocrinol"},{"issue":"5","key":"2710_CR36","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2337\/db10-0452","volume":"60","author":"C Guinez","year":"2011","unstructured":"Guinez C, Filhoulaud G, Rayah-Benhamed F, Marmier S, Dubuquoy C, Dentin R, et al. O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver. Diabetes. 2011;60(5):1399\u2013413.","journal-title":"Diabetes"},{"issue":"5","key":"2710_CR37","first-page":"230","volume":"13","author":"F Benhamed","year":"2015","unstructured":"Benhamed F, Filhoulaud G, Caron S, Lefebvre P, Staels B, Postic C. O-GlcNAcylation links ChREBP and FXR to glucose-sensing. Front Endocrinol. 2015;13(5):230.","journal-title":"Front Endocrinol"},{"issue":"1","key":"2710_CR38","doi-asserted-by":"publisher","first-page":"G107","DOI":"10.1152\/ajpgi.00391.2009","volume":"298","author":"N Lanthier","year":"2010","unstructured":"Lanthier N, Molendi-Coste O, Horsmans Y, van Rooijen N, Cani PD, Leclercq IA. Kupffer cell activation is a causal factor for hepatic insulin resistance. Am J Physiol Gastrointestin Liver Physiology. 2010;298(1):G107-16.","journal-title":"Am J Physiol Gastrointestin Liver Physiology."},{"issue":"8","key":"2710_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/foods10081854","volume":"10","author":"S Jiang","year":"2021","unstructured":"Jiang S, Liu H, Li C. Dietary regulation of oxidative stress in chronic metabolic diseases. Foods. 2021;10(8):1854.","journal-title":"Foods"},{"issue":"2","key":"2710_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1039\/C1FO10111K","volume":"3","author":"M Janevski","year":"2012","unstructured":"Janevski M, Ratnayake S, Siljanovski S, McGlynn MA, Cameron-Smith D, Lewandowski P. Fructose containing sugars modulate mRNA of lipogenic genes ACC and FAS and protein levels of transcription factors ChREBP and SREBP1c with no effect on body weight or liver fat. Food Funct. 2012;3(2):141\u20139.","journal-title":"Food Funct"},{"issue":"3","key":"2710_CR41","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1172\/JCI99009","volume":"128","author":"S Softic","year":"2018","unstructured":"Softic S, Gupta MK, Wang GX, Fujisaka S, O\u2019Neill BT, Rao TN, et al. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. J Clin Invest. 2018;128(3):1199.","journal-title":"J Clin Invest"},{"key":"2710_CR42","doi-asserted-by":"crossref","unstructured":"Geidl-Flueck B, Gerber PA. Fructose drives de novo lipogenesis, affecting metabolic health. Journal of Endocrinology. 2023 May 1;257(2):e220270 .","DOI":"10.1530\/JOE-22-0270"},{"issue":"7121","key":"2710_CR43","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature05485","volume":"444","author":"GS Hotamisligil","year":"2006","unstructured":"Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860\u20137.","journal-title":"Nature"},{"issue":"01","key":"2710_CR44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1055\/s-0043-118666","volume":"50","author":"S Kakino","year":"2018","unstructured":"Kakino S, Ohki T, Nakayama H, Yuan X, Otabe S, Hashinaga T, et al. Pivotal role of TNF-\u03b1 in the development and progression of nonalcoholic fatty liver disease in a murine model. Horm Metab Res. 2018;50(01):80\u20137.","journal-title":"Horm Metab Res"},{"issue":"1","key":"2710_CR45","first-page":"5076858","volume":"2020","author":"H Alzamil","year":"2020","unstructured":"Alzamil H. Elevated serum TNF-\u03b1 is related to obesity in type 2 diabetes mellitus and is associated with glycemic control and insulin resistance. J Obesity. 2020;2020(1):5076858.","journal-title":"J Obesity"},{"issue":"1","key":"2710_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jhep.2022.01.016","volume":"77","author":"D Marti-Aguado","year":"2022","unstructured":"Marti-Aguado D, Clemente-Sanchez A, Bataller R. Cigarette smoking and liver diseases. J Hepatol. 2022;77(1):191\u2013205.","journal-title":"J Hepatol"},{"issue":"7","key":"2710_CR47","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/17474124.2021.1914587","volume":"15","author":"G Tarantino","year":"2021","unstructured":"Tarantino G, Citro V, Balsano C. Liver-spleen axis in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2021;15(7):759\u201369.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"2710_CR48","doi-asserted-by":"publisher","first-page":"281","DOI":"10.21608\/ajgh.2024.313440.1061","volume":"7","author":"EM Foda","year":"2024","unstructured":"Foda EM, Saleh SA, Eskandaros MS, El-Khazragy NN, Abu Bakr HM, Massoud YM, et al. Significance of the influence of patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 polymorphism on non alcoholic fatty liver disease. African Journal of Gastroenterology and Hepatology. 2024;7(1):281\u201390.","journal-title":"African Journal of Gastroenterology and Hepatology"},{"issue":"4","key":"2710_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3160","volume":"22","author":"K Narayanasamy","year":"2020","unstructured":"Narayanasamy K, Karthick R, Panneerselvam P, Mohan N, Ramachandran A, Prakash R, et al. Association of metabolic syndrome and patatin-like phospholipase 3\u2013rs738409 gene variant in non-alcoholic fatty liver disease among a Chennai-based south Indian population. J Gene Med. 2020;22(4):e3160.","journal-title":"J Gene Med"},{"issue":"1","key":"2710_CR50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/jgh.12656","volume":"30","author":"J Shen","year":"2015","unstructured":"Shen J, Wong GL, Chan HL, Chan RS, Chan HY, Chu WC, et al. PNPLA 3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2015;30(1):139\u201346.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"2710_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41387-020-00130-3","volume":"10","author":"SW Wang","year":"2020","unstructured":"Wang SW, Sheng H, Bai YF, Weng YY, Fan XY, Lou LJ, et al. Neohesperidin enhances PGC-1\u03b1-mediated mitochondrial biogenesis and alleviates hepatic steatosis in high fat diet fed mice. Nutr Diabetes. 2020;10(1):27.","journal-title":"Nutr Diabetes"},{"issue":"4","key":"2710_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.108327","volume":"301","author":"M Chen","year":"2025","unstructured":"Chen M, Ghelfi M, Poon JF, Jeon N, Boccalon N, Rubsamen M, et al. Antioxidant-independent activities of alpha-tocopherol. J Biol Chem. 2025;301(4):108327.","journal-title":"J Biol Chem"},{"issue":"3","key":"2710_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30030653","volume":"30","author":"B Es-Sai","year":"2025","unstructured":"Es-Sai B, Wahnou H, Benayad S, Rabbaa S, Laaziouez Y, El Kebbaj R, et al. Gamma-tocopherol: a comprehensive review of its antioxidant, anti-inflammatory, and anticancer properties. Molecules. 2025;30(3):653.","journal-title":"Molecules"},{"issue":"5","key":"2710_CR54","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","volume":"66","author":"AR Mridha","year":"2017","unstructured":"Mridha AR, Wree A, Robertson AA, Yeh MM, Johnson CD, Van Rooyen DM, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017;66(5):1037\u201346.","journal-title":"J Hepatol"},{"issue":"13","key":"2710_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.780496","volume":"8","author":"L Yu","year":"2022","unstructured":"Yu L, Hong W, Lu S, Li Y, Guan Y, Weng X, et al. The NLRP3 inflammasome in non-alcoholic fatty liver disease and steatohepatitis: therapeutic targets and treatment. Front Pharmacol. 2022;8(13):780496.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2710_CR56","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/osp4.460","volume":"7","author":"M Tokoro","year":"2021","unstructured":"Tokoro M, Gotoh K, Kudo Y, Hirashita Y, Iwao M, Arakawa M, et al. \u03b1-Tocopherol suppresses hepatic steatosis by increasing CPT-1 expression in a mouse model of diet-induced nonalcoholic fatty liver disease. Obes Sci Pract. 2021;7(1):91\u20139.","journal-title":"Obes Sci Pract"},{"issue":"1","key":"2710_CR57","doi-asserted-by":"publisher","first-page":"101937","DOI":"10.1016\/j.redox.2021.101937","volume":"42","author":"MC Podszun","year":"2021","unstructured":"Podszun MC, Frank J. Impact of vitamin E on redox biomarkers in non-alcoholic fatty liver disease. Redox Biol. 2021;42(1):101937.","journal-title":"Redox Biol"},{"key":"2710_CR58","doi-asserted-by":"publisher","DOI":"10.1177\/20420188241252543","volume":"15","author":"Z Pan","year":"2024","unstructured":"Pan Z, Khatry MA, Yu ML, Choudhury A, Sebastiani G, Alqahtani SA, et al. MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight. Ther Adv Endocrinol Metab. 2024;15:20420188241252543.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"3","key":"2710_CR59","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/MOL.0b013e328338ca61","volume":"21","author":"S Romeo","year":"2010","unstructured":"Romeo S, Huang-Doran I, Baroni MG, Kotronen A. Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Curr Opin Lipidol. 2010;21(3):247\u201352 (Jun 1;).","journal-title":"Curr Opin Lipidol"},{"key":"2710_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.595371","volume":"8","author":"AP Bovi","year":"2021","unstructured":"Bovi AP, Marciano F, Mandato C, Siano MA, Savoia M, Vajro P. Oxidative stress in non-alcoholic fatty liver disease. An updated mini review. Front Med. 2021;8:595371.","journal-title":"Front Med"},{"issue":"10","key":"2710_CR61","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.bcp.2006.02.009","volume":"71","author":"BB Aggarwal","year":"2006","unstructured":"Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006;71(10):1397\u2013421.","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"2710_CR62","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nri910","volume":"2","author":"Q Li","year":"2002","unstructured":"Li Q, Verma IM. NF-\u03baB regulation in the immune system. Nat Rev Immunol. 2002;2(10):725\u201334.","journal-title":"Nat Rev Immunol"},{"issue":"21","key":"2710_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/nu15214569","volume":"15","author":"S Wu","year":"2023","unstructured":"Wu S, Jia W, He H, Yin J, Xu H, He C, et al. A new dietary fiber can enhance satiety and reduce postprandial blood glucose in healthy adults: a randomized cross-over trial. Nutrients. 2023;15(21):4569.","journal-title":"Nutrients"},{"issue":"3","key":"2710_CR64","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ajcnut.2024.01.007","volume":"119","author":"H Huber","year":"2024","unstructured":"Huber H, Schieren A, Holst JJ, Simon MC. Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions\u2013a narrative review. Am J Clin Nutr. 2024;119(3):599\u2013627.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"2710_CR65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s43066-023-00282-8","volume":"13","author":"A Attia","year":"2023","unstructured":"Attia A, Labib NA, Abdelzaher NE, Musa S, Atef M. Lifestyle determinants as predictor of severity of metabolic-associated fatty liver disease (MAFLD). Egypt Liver J. 2023;13(1):47.","journal-title":"Egypt Liver J"},{"issue":"1","key":"2710_CR66","first-page":"11","volume":"6","author":"AA Moneim","year":"2018","unstructured":"Moneim AA, Tayel DI, Zeid A, Darwish O, Matrawy K, Eid M. Dietary intervention in clinical improvement of nonalcoholic fatty liver patients. World. 2018;6(1):11\u201322.","journal-title":"World"},{"issue":"12","key":"2710_CR67","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.5812\/hepatmon.15227","volume":"13","author":"A Ghaemi","year":"2013","unstructured":"Ghaemi A, Taleban FA, Hekmatdoost A, Rafiei A, Hosseini V, Amiri Z, et al. How much weight loss is effective on nonalcoholic fatty liver disease? Hepat Mon. 2013;13(12):e152-27.","journal-title":"Hepat Mon"},{"key":"2710_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.948655","volume":"9","author":"H Kord Varkaneh","year":"2022","unstructured":"Kord Varkaneh H, Salehi Sahlabadi A, G\u0103man MA, Rajabnia M, Sedanur Macit-\u00c7elebi M, Santos HO, et al. Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: a randomized controlled trial. Front Nutr. 2022;9:948655.","journal-title":"Front Nutr"},{"issue":"2","key":"2710_CR69","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68(2):268\u201379.","journal-title":"J Hepatol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02710-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02710-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02710-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:18:45Z","timestamp":1758719925000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-025-02710-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2710"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02710-7","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted after obtaining approval from the Ethics Unit of Suez University, Suez, Egypt, Approval #: Approval #60323.All subjects were informed and gave their voluntary, written informed consent.It is declared that all methods were carried out following relevant guidelines and regulations. It was performed according to the recommendations of Good Clinical Practice and the Declaration of Helsinki (2013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"286"}}